Therapeutic devices Segment to Account for Largest Market Share by Type in Americas Sleep Apnea Market during 2022–2030

According to our new research study on " Americas Sleep Apnea Market Forecast to 2030 – COVID-19 Impact and Regional Analysis – by Type, and End-user," the market is expected to grow from US$ 2,454.20 million in 2022 and is expected to reach to a value of US$ 4,103.24 million by 2030, it is anticipated to record a CAGR of 6.6% from 2022 to 2030. The report highlights the key factors driving the Americas sleep apnea market growth and prominent players with their developments in the market.  

Based on Type, the Americas sleep apnea market is bifurcated into diagnostic devices and therapeutic devices. Diagnostic devices is further sub-segmented as polysomnography devices (PSG), home sleep testing devices, pulse oximeters, actigraphy devices, and others. Therapeutic devices is further sub-segmented as PAP, sleep masks, oral appliances, and others. The therapeutics segment held the largest market share in 2022 and diagnostic devices is anticipated to register the highest CAGR  during the forecast period (2022–2030).

Based on the region, US is holding the largest market share of the region in the Americas sleep apnea market.

The Americas sleep apnea market is expected to grow owing to easy access to Americas sleep apnea and a rise in surgical procedures in the country. Sleep apnea is one of the major health issues and a common sleep disorder in the US. The American Sleep Apnea Association estimates that 38,000 people in the country die each year from heart disease with sleep apnea as a complication. In addition to the increasing number of deaths associated with sleep apnea and the rising awareness about risk factors of sleep apnea, the growing importance of sleep testing in adults and pediatric populations favors the sleep apnea market growth.

Excessive daytime sleepiness among people with narcolepsy or obstructive sleep apnea (OSA) at work, at home, or in daily activities hampers their daily lives. In March 2019, Jazz Pharmaceuticals plc received US Food and Drug Administration (FDA) approval for its product named "Sunosi" (Solriamfetol), prescribed to improve wakefulness among adult patients suffering from excessive daytime sleepiness associated with narcolepsy or OSA. The increasing availability of such medicines bolsters the growth of sleep apnea in the US.

ResMed Inc; Nihon Kohden Corp; Fisher & Paykel Healthcare Ltd, Koninklijke Philips NV, Cadwell Industries Inc; Natus Medical Inc; Compumedics Limited; LivaNova Plc; Invacare Corp; Braebon Medical Corporation. are among the key companies operating in the Americas sleep apnea market.

Companies operating in the Americas sleep apnea market adopt various organic and inorganic strategies. Organic strategies mainly include product launches and product approvals. Acquisitions, collaborations, and partnerships are among the inorganic growth strategies witnessed in the Americas sleep apnea market. These growth strategies allow the market players to expand their businesses and enhance their geographic presence, thereby contributing to the overall Americas sleep apnea market growth. Further, acquisition and partnership strategies help them strengthen their customer base and expand their product portfolios.

A few of the significant developments by key Americas sleep apnea market players are listed below.

• In Feb-2021, Sleepmate products have been providing high quality and reliable sleep diagnostic sensor solutions for more than 30 years. Cadwell is now honored to include the Sleepmate portfolio as an integral part of our comprehensive sleep diagnostic solutions for both in-lab and at-home testing.
• In Feb-2022, LivaNova PLC announced the first patient implanted in the investigational device exemption (IDE) clinical study, “Treating Obstructive Sleep Apnea using Targeted Hypoglossal Neurostimulation” (OSPREY). The randomized controlled trial (RCT) seeks to demonstrate the safety and effectiveness of the LivaNova aura6000 System, an implantable hypoglossal neurostimulator intended to treat adult patients with moderate to severe obstructive sleep apnea (OSA).
• In June-2021, LivaNova PLC received approval from the U.S. Food and Drug Administration (FDA) to proceed with its investigational device exemption (IDE) clinical study, “Treating Obstructive Sleep Apnea using Targeted Hypoglossal Neurostimulation (OSPREY).” The OSPREY study will seek to demonstrate the safety and effectiveness of the aura6000 System, the LivaNova implantable hypoglossal neurostimulator intended to treat adult patients with moderate to severe obstructive sleep apnea (OSA).

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com